COVID-19

Higher ivermectin dose, longer duration still futile for COVID, trial finds CIDRAP

A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.

...

FDA’s own reputation could be restraining its misinfo fight WASHINGTON (AP) — The government agency responsible for tracking down contaminated peanut butter and defective pacemakers is taking on a new health hazard: online misinformation. It’s an unlikely role for the Food and Drug Administration, a sprawling, century-old bureaucracy that for decades directed most its communications toward doctors and corporations. AP NEWS

...

The pandemic has irreversibly changed America’s health care system. Here’s why we will all be feeling the consequences of delayed care for years to come Elective surgery delays can be detrimental in both preventive and curative care, allowing disease progression or leading to premature death. YahooFinance

...

XBB.1.5 Omicron subvariant now dominant in all US regions CIDRAP

In its new variant estimates today, the Centers for Disease Control and Prevention (CDC) said the XBB.1.5 Omicron subvariant is now dominant the northwestern region, making it the most

Also, the more transmissible variant expanded its footprint in areas where it already dominates, and in the United States as a whole, it accounts for an estimated 80.2% of samples, up steadily from 74.7% the previous week.

...